Biomarker-Driven Lung Cancer

>

Latest News

Ivonescimab Reduces Risk of Progression Over Pembrolizumab in PD-L1+ Advanced NSCLC
Ivonescimab Reduces Risk of Progression Over Pembrolizumab in PD-L1+ Advanced NSCLC

October 24th 2024

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer.

Shifting the Paradigm: Challenges, Opportunities and Methodologies in Studying Rare Cancers
Shifting the Paradigm: Challenges, Opportunities and Methodologies in Studying Rare Cancers

October 14th 2024

STX-241 Trial Begins for EGFR TKI-Resistant NSCLC Treatment
STX-241 Trial Begins for EGFR TKI-Resistant NSCLC Treatment

October 8th 2024

Long-Term Data Confirms Cemiplimab Benefits in High PD-L1 NSCLC
Long-Term Data Confirms Cemiplimab Benefits in High PD-L1 NSCLC

October 8th 2024

Olomorasib Combo Elicits Favorable Efficacy in NSCLC
Olomorasib Combo Elicits Favorable Efficacy in NSCLC

September 27th 2024

Video Series
Video Interviews

More News